Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v16.i2.20
36 pages

Targeted Delivery of Radiolabeled Imaging and Therapeutic Agents: Bifunctional Radiopharmaceuticals

Hideo Saji
Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan


Clinical application of radioactive diagnostic and therapeutic agents constitutes one of the great advances in noninvasive medicine, nuclear medicine. The radioactive agents used in the nuclear medical field are called "radiopharmaceuticals," and are required to exhibit high and specific localization of radioactivity into target tissue. Among radionuclides used in radiopharmaceuticals, radiometals such as 99mTc and 111In have received much attention because of their nuclear physical characteristics and widespread availability. However, since these metallic elements are not constituents of bioactive molecules, they cannot simply replace common constituent atoms in biologically interesting compounds. Thus, demand for biospecific radiopharmaceuticals constitutes a great challenge in rational design of biologically active molecules labeled with metallic radionuclides, and evolves into a generation of bifunctional radiopharmaceuticals. Molecules contain both a biologically active site and a chelating group for binding the metallic radionuclide in which attachment of a chelating group does not affect the inherent biospecificity of the mother compound. This paper describes recent progress in research of macro- and small-molecular bifunctional radiopharmaceuticals for targeted diagnosis and therapy.

Articles with similar content:

Nuclear Matrix and Protein Kinase CK2 Signaling
Critical Reviews™ in Eukaryotic Gene Expression, Vol.9, 1999, issue 3-4
Khalil Ahmed
Functional Links between Nuclear Structure, Gene Expression, DNA Replication, and Methylation
Critical Reviews™ in Eukaryotic Gene Expression, Vol.9, 1999, issue 3-4
Heinrich Leonhardt, M. Cristina Cardoso, Hans-Peter Rahn
Stem Cell Therapy for Diabetes Mellitus: Recent Progress and Hurdles
Critical Reviews™ in Eukaryotic Gene Expression, Vol.29, 2019, issue 5
Ammara Saleem, Uzma Saleem, Mohammad Saleem, Muhammad Furqan Akhtar, Sara Zahid, Sammia Gul Niazi, Shakila Sabir, Muhammad Naeem
Human High Molecular Weight-Melanoma-Associated Antigen (HMW-MAA): A Melanoma Cell Surface Chondroitin Sulfate Proteoglycan (MSCP) with Biological and Clinical Significance
Critical Reviews™ in Immunology, Vol.24, 2004, issue 4
Soldano Ferrone, Xinhui Wang, Toshiro Kageshita, Chien-Chung Chang, Michael R. Campoli, James B. McCarthy
Protein Kinase C Control of Gene Expression
Critical Reviews™ in Eukaryotic Gene Expression, Vol.11, 2001, issue 1-3
Carlo Ventura, Margherita Maioli